Upstream Bio (UPB) Competitors $7.98 -0.25 (-3.04%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.98 0.00 (0.00%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends UPB vs. EVO, IRON, ARQT, AMPH, IMCR, AAPG, KNSA, DYN, GPCR, and ARDXShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Evotec Disc Medicine Arcutis Biotherapeutics Amphastar Pharmaceuticals Immunocore Ascentage Pharma Group International Kiniksa Pharmaceuticals Dyne Therapeutics Structure Therapeutics Ardelyx Evotec (NASDAQ:EVO) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation. Do insiders and institutionals hold more shares of EVO or UPB? 5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, EVO or UPB? Upstream Bio has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$845.74M1.86-$90.82MN/AN/AUpstream BioN/AN/AN/AN/AN/A Does the MarketBeat Community favor EVO or UPB? Evotec received 2 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformEvotecOutperform Votes654.55% Underperform Votes545.45% Upstream BioOutperform Votes4100.00% Underperform VotesNo Votes Do analysts rate EVO or UPB? Evotec currently has a consensus target price of $5.93, indicating a potential upside of 33.63%. Upstream Bio has a consensus target price of $56.50, indicating a potential upside of 608.02%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts clearly believe Upstream Bio is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer EVO or UPB? In the previous week, Evotec had 2 more articles in the media than Upstream Bio. MarketBeat recorded 2 mentions for Evotec and 0 mentions for Upstream Bio. Evotec's average media sentiment score of 0.58 beat Upstream Bio's score of 0.00 indicating that Evotec is being referred to more favorably in the media. Company Overall Sentiment Evotec Positive Upstream Bio Neutral Is EVO or UPB more profitable? Company Net Margins Return on Equity Return on Assets EvotecN/A N/A N/A Upstream Bio N/A N/A N/A SummaryEvotec beats Upstream Bio on 6 of the 10 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$427.73M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / SalesN/A313.78457.6880.73Price / CashN/A67.8344.0437.47Price / BookN/A6.747.634.64Net IncomeN/A$138.11M$3.18B$245.69M7 Day Performance5.00%-2.02%-1.82%-2.63%1 Month Performance-26.18%-1.54%0.22%-2.37%1 Year PerformanceN/A-3.14%17.49%13.65% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream BioN/A$7.98-3.0%$56.50+608.0%N/A$441.10MN/A0.0038Upcoming EarningsEVOEvotec1.7973 of 5 stars$4.58-0.2%$5.93+29.5%-39.5%$1.62B$845.74M0.005,061IRONDisc Medicine1.8805 of 5 stars$54.10flat$88.90+64.3%-15.9%$1.61BN/A-13.5930Insider TradeNews CoverageARQTArcutis Biotherapeutics2.4746 of 5 stars$12.78+3.8%$16.60+29.9%+40.5%$1.50B$59.61M-7.14150AMPHAmphastar Pharmaceuticals4.434 of 5 stars$31.02-2.3%$50.33+62.3%-39.0%$1.49B$644.40M10.341,761IMCRImmunocore1.433 of 5 stars$29.60-0.5%$65.64+121.7%-57.4%$1.48B$249.43M-31.16320AAPGAscentage Pharma Group InternationalN/A$18.24+5.7%N/AN/A$1.44BN/A0.00600News CoverageGap UpKNSAKiniksa Pharmaceuticals3.1847 of 5 stars$19.74+0.5%$36.60+85.4%+0.3%$1.43B$270.26M-140.99220Upcoming EarningsDYNDyne Therapeutics3.0848 of 5 stars$13.91-1.0%$49.91+258.8%-37.9%$1.42BN/A-3.91100GPCRStructure Therapeutics2.5058 of 5 stars$24.39+0.1%$81.29+233.3%-42.2%$1.40BN/A-32.96136ARDXArdelyx4.3501 of 5 stars$5.79+2.3%$9.42+62.6%-40.5%$1.37B$124.46M-19.3090Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies EVO Alternatives IRON Alternatives ARQT Alternatives AMPH Alternatives IMCR Alternatives AAPG Alternatives KNSA Alternatives DYN Alternatives GPCR Alternatives ARDX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
